Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Autolus Therapeutics plc files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
1.21
1.69
1.41
2.91
1.7
10.1
75.4
Cost of revenue
0
11.4
96.4
Gross profit
1.7
-1.27
-21
Research and development
10.4
16
36.2
105
135
111
117
130
138
118
Selling, general and administrative
46.7
102
132
General and administrative
5.15
9.1
22.8
39.5
35
31.9
31.9
46.7
Operating expenses
14.4
23.4
57.5
Operating income
-23.4
-57.5
-146
-168
-141
-143
-180
-241
-271
Interest expense
0
0
1.11
8.91
45.1
9.29
36.7
Interest income
0.08
0.08
1.53
2.54
0.54
0.26
1.71
13.5
32.4
19
Other non-operating income
0.05
0.04
5.5
7.06
1.89
-0.99
-5.16
-28.7
22.3
-15
Pre-tax income
-14.3
-23.4
-52
-139
-166
-142
-149
-208
-219
-286
Income tax
-1.78
-3.65
-7.28
-15.2
-24.2
0.06
0.27
-0.02
1.53
1.97
Net income
-12.6
-19.7
-44.8
-124
-142
-142
-149
-208
-221
-288
EBITDA
-22.4
-55.8
-141
-162
-133
-136
-173
-234
-262
EPS, basic
-1.26
-1.43
-1.42
-2.88
-2.76
-1.97
-1.57
-1.20
-0.86
-1.08
EPS, diluted
-1.26
-1.43
-1.42
-2.88
-2.76
-1.97
-1.57
-1.20
-0.86
-1.08
Shares, basic (weighted)
9.93
13.8
31.6
43.1
51.6
72.1
95
174
255
266
Shares, diluted (weighted)
9.93
13.8
31.6
43.1
51.6
72.1
95
174
255
266
Balance sheet
FY2016
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
28.1
137
247
211
154
310
382
240
227
104
Short-term investments
0
361
197
Receivables
0
0.12
0.11
0.02
24
Inventory
0
4.14
33.2
Other current assets
0
0.72
0.28
0
0.24
0.2
0
1.57
0
Total current assets
142
259
249
197
347
426
275
661
436
Property, plant and equipment
6.18
13.5
28.2
38
33.5
35.2
34.9
49.6
63.6
Lease right-of-use assets
23.4
51.6
18.8
23.2
60.8
55.5
64.9
Intangible assets
0
0.4
0.25
0.16
0.07
0
0
12.4
19.8
Total assets
149
273
304
294
406
490
375
783
589
Accounts payable
1.95
3.04
1.08
2.26
0.43
0.53
0.1
1.97
3.08
Accrued liabilities
3.09
14.1
21.4
27.8
23.7
40.8
39.6
52.3
55.8
Deferred revenue
0
3.5
Total current liabilities
5.03
17.1
25
33.6
28.6
46.4
44.7
60.7
73.4
Long-term debt
0.76
0.38
0
Lease liabilities
23.7
50.6
16.5
19.2
47.9
49.6
66.8
Other non-current liabilities
0
0.13
0.12
0.36
0.43
0.48
Total liabilities
6.06
17.7
48.7
84.2
92.2
192
264
355
411
Total debt
0.76
0.38
0
Paid-in capital
194
358
501
595
843
1,008
1,019
1,556
1,570
Retained earnings
-47.9
-92.7
-237
-379
-521
-670
-879
-1,099
-1,387
Other comprehensive income
-3.85
-9.92
-8.69
-5.86
-8.57
-38.9
-29
-29.2
-5.36
Shareholders' equity
30.7
143
255
255
210
313
299
111
427
178
Total equity
30.7
143
255
255
210
313
299
111
427
178
Total liabilities and equity
149
273
304
294
406
490
375
783
589
Cash flow statement
FY2016
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-12.6
-19.7
-44.8
-124
-142
-142
-149
-208
-221
-288
Depreciation and amortization
0.48
1.01
1.71
4.61
5.66
8.46
7.42
6.57
7.55
8.3
Stock-based compensation
2.26
3.15
6.77
30.4
20
9.94
12
11.2
15.5
14.4
Deferred income tax
0
0
-0.41
-1.34
-0.11
-0.21
-0.99
-0.18
-0.63
Change in receivables
0
-24.2
Change in inventory
0
-4.23
-40.3
Change in payables
0.51
0.43
0.84
-1.45
1.44
-1.82
0.02
-0.51
1.59
1.3
Cash from operations
-9.85
-16.4
-31.5
-101
-118
-118
-112
-146
-206
-284
Capital expenditures
-1.86
-2.88
-9.12
-18.3
-14.7
-8.86
-10.8
-11
-22.1
-19
Purchases of investments
0
-360
-243
Cash from investing
-1.86
-2.88
-9.53
-18.7
-14.7
-8.86
-10.8
-11
-395
158
Stock issued
32.2
128
157
116
79.8
246
164
0
550
0
Cash from financing
32.2
128
157
109
74.4
284
224
-0.88
590
-4.34
Exchange rate effect
-2.66
0.56
-5.83
5.16
0.68
-0.75
-28.4
15
-0.26
6.28
Net change in cash
17.9
109
110
-6.13
-57.3
157
72.1
-142
-11.5
-123
Free cash flow
-11.7
-19.2
-40.7
-120
-132
-127
-123
-157
-228
-303
Interest paid
0
0
1.54
1.84
Income taxes paid
1.54
-19.8
-24.7
-19.6
0.55
2.39
1.97
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $1.86 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
15.7%
Gross profit / revenue.
Operating margin
-210.8%
Operating income / revenue.
EBITDA margin
-203.4%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-238.1%
Pre-tax income / revenue.
Net margin
-238.7%
Net income / revenue.
FCF margin
-198.3%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-192.2%
Cash from operations / revenue.
Return on equity (ROE)
-374.3%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-56.8%
Net income / average total assets.
R&D / revenue
95.9%
Research and development expense / revenue.
SG&A / revenue
130.5%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
13.2%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
6.1%
Capital expenditures / revenue.
D&A / revenue
7.4%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
644.9%
Revenue vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
-58.3%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-15.8%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-3.2%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-24.7%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
6.3%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
14.9%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
4.3%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
41.0%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
38.9%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
4.89x
Current assets / current liabilities.
Quick ratio
3.58x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
2.93x
(Cash + short-term investments) / current liabilities.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$1.05
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.44
Revenue / diluted weighted shares.
FCF per share
-$0.87
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.85
Cash from operations / diluted weighted shares.
Book value per share
$0.28
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
4.21x
Market cap / revenue.
P/B
6.60x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
8.77x
Market cap / tangible book value, when positive.
EV/Sales
2.49x
Enterprise value / revenue.
FCF yield
-47.1%
Free cash flow / market cap.
Earnings yield
-56.7%
Net income / market cap (the inverse of P/E).
What was Autolus Therapeutics plc's revenue in fiscal 2025?
Autolus Therapeutics plc reported revenue of $75.4M for fiscal 2025, 644.9% higher than the year before.
Was Autolus Therapeutics plc profitable in fiscal 2025?
No. It reported a net loss of $287.5M.
How much free cash flow did Autolus Therapeutics plc generate in fiscal 2025?
Cash from operations of $283.6M minus capital expenditures of $19.0M left free cash flow of -$302.6M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.